Antidepressants are not inherently bad for you, but they do carry real side effects and risks that vary widely depending on the medication, the dose, and your individual biology. About 67% of people who try up to four different antidepressant treatments reach full remission from depression, and newer reanalysis of major trial data suggests that number may be even higher over time, with roughly 75% of patients achieving remission within six months. So these medications genuinely help most people who take them. But “not bad” and “without downsides” are very different things, and the honest answer lives in the details.
Common Side Effects Most People Notice
The most frequently reported side effects of antidepressants fall into a few broad categories: changes in weight, sexual problems, sleep disruption, and digestive issues like nausea. SSRIs, the most widely prescribed class, can cause weight gain, increased waist circumference, higher cholesterol, abnormal blood sugar processing, and insulin resistance over time. These aren’t rare edge cases. They’re common enough that many people notice at least one within the first few weeks of starting treatment.
Sexual side effects, including low libido and difficulty reaching orgasm, are particularly common with SSRIs and SNRIs. For some people these fade after a few weeks; for others they persist as long as the medication continues. Sleep changes cut both ways: some antidepressants cause drowsiness, while others trigger insomnia or unusually vivid dreams.
Not all antidepressants carry the same metabolic profile. Bupropion, for example, is generally considered weight-neutral and may even promote modest weight loss. It also doesn’t significantly affect cholesterol or blood sugar. If metabolic side effects are a concern, this distinction matters when discussing options with a prescriber.
What Happens to Your Liver and Kidneys
A study of over 1,700 hospitalized patients on antidepressant monotherapy found that all six medications studied raised liver enzyme levels to some degree. Duloxetine (an SNRI) showed the most pronounced changes. The study also found that venlafaxine, duloxetine, and fluoxetine lowered sodium and chloride levels within two weeks of treatment. Kidney effects were generally mild, with sertraline being the only one to meaningfully reduce uric acid levels.
For most people, these shifts stay within a manageable range. But if you already have liver or kidney concerns, or if you’re on other medications that stress those organs, these effects become more relevant. Routine blood work during the first months of treatment can catch problems early.
The Suicidality Warning for Young People
Every antidepressant in the United States carries an FDA black box warning, the most serious type of drug safety alert, about an increased risk of suicidal thinking and behavior in children and adolescents. This warning is based on a combined analysis of short-term trials (up to four months) of nine antidepressant drugs in young people with depression, OCD, and other psychiatric conditions.
The warning applies specifically to patients under 18, and the risk is highest during the first few months of treatment or when doses change. It does not mean antidepressants cause suicide in adults, though close monitoring during early treatment is standard practice for all age groups. The risk needs to be weighed against the very real danger of leaving serious depression untreated in a young person.
Serotonin Syndrome: Rare but Serious
Serotonin syndrome happens when too much serotonin accumulates in the body. Mild cases cause shivering, diarrhea, and restlessness. Severe cases can trigger high fever, seizures, irregular heartbeat, and unconsciousness. It is most often caused by combining two or more medications that boost serotonin, such as taking an antidepressant alongside certain migraine drugs or opioid pain medications. It can also result from an intentional overdose.
Taking a single antidepressant at the prescribed dose rarely causes serotonin syndrome on its own. The real danger comes from drug combinations, including interactions with supplements like St. John’s wort or illicit drugs like MDMA. If you’re prescribed an antidepressant, making sure every provider knows your full medication list is the simplest way to avoid this.
Long-Term Metabolic Risks
Longer antidepressant use has been linked to a higher incidence of metabolic abnormalities. Older tricyclic antidepressants carry the strongest association: patients taking tricyclics had 2.27 times the odds of developing metabolic syndrome (a cluster of conditions including high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol) compared to people not on antidepressants.
SSRIs also carry metabolic risks, though generally milder than tricyclics. The concern is that metabolic syndrome itself raises the risk of heart disease, stroke, and type 2 diabetes. For someone who plans to be on an antidepressant for years, periodic monitoring of blood pressure, waist circumference, blood sugar, and cholesterol is a practical safeguard. Some medications in the antidepressant family, particularly bupropion and a few others, don’t carry these metabolic risks at clinically meaningful levels.
Stopping Antidepressants: Withdrawal Is Real
Antidepressants are not addictive in the way that benzodiazepines or opioids are. They don’t produce cravings, compulsive drug-seeking, or the escalating need for a high. But your body does adapt to them physically, and stopping abruptly can cause a withdrawal syndrome that starts within two to four days and typically lasts one to two weeks, though it occasionally persists for up to a year.
The symptoms are distinctive: flu-like fatigue and achiness, insomnia with vivid nightmares, nausea, dizziness, strange “electric shock” sensations in the head or limbs, and heightened anxiety or irritability. Medications with shorter half-lives (meaning they leave your system faster) tend to cause worse withdrawal. Tapering gradually over six to eight weeks significantly reduces the risk. If you’ve been on an antidepressant for less than four weeks, tapering usually isn’t necessary. Fluoxetine (Prozac), which stays in your system much longer than other SSRIs, also tends to cause fewer withdrawal problems.
The clinical distinction matters: physical dependence (your body adjusting to a drug) is not the same as addiction (compulsive use despite harm). Antidepressants produce the first without the second. Unlike benzodiazepines, which can actually worsen depression and anxiety over time, antidepressants don’t tend to make the conditions they treat worse.
Why the Same Pill Affects People Differently
Your body breaks down antidepressants using a family of liver enzymes, and the genes that code for those enzymes vary significantly from person to person. These genetic differences sort people into categories: poor metabolizers (who break down drugs slowly, leading to higher blood levels and more side effects), normal metabolizers, and ultrarapid metabolizers (who clear drugs so fast they may not get a therapeutic effect at all). The most relevant enzymes for antidepressant metabolism vary by ethnicity and population, which partly explains why the same medication at the same dose can be barely noticeable for one person and intolerable for another.
Pharmacogenomic testing, a simple cheek swab, can identify your metabolizer status for the most relevant enzymes and help narrow down which antidepressants are likely to work well and which are likely to cause problems. It’s not a crystal ball, but it removes some of the trial-and-error from the process.
Pregnancy Considerations
Women who continue antidepressants during pregnancy face roughly 2.6 times the odds of their newborn experiencing postnatal adaptation syndrome compared to women who stop the medication before delivery. This syndrome is temporary, involving irritability, feeding difficulties, and respiratory issues in the first days of life. Importantly, research has not found an increased risk of persistent pulmonary hypertension or congenital malformations in babies exposed to antidepressants in utero.
The decision to continue or stop an antidepressant during pregnancy involves weighing the baby’s short-term adaptation risk against the mother’s risk of relapsing into severe depression, which itself carries consequences for both parent and child. There is no risk-free option, only a choice between two sets of risks.